Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 3/20 | 0.34 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | STING1 | Q86WV6 | 8/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2717923 | 0.83 | TAAR1 (0.38) | IMPDH2IMPDH1HPGDTAAR1 | |
| SCHEMBL20010243 | 0.77 | IMPDH2 (0.37) | IMPDH2IMPDH1HPGDTAAR1STING1 | |
| SCHEMBL2720283 | 0.72 | TAAR1 (0.35) | IMPDH2HPGDTAAR1STING1 | |
| SCHEMBL14929368 | 0.71 | HINT1 (0.45) | HPGDSTING1PDE3BPDE3A | |
| SCHEMBL14946309 | 0.71 | HINT1 (0.45) | HPGDSTING1PDE3BPDE3A | |
| SCHEMBL12851721 | 0.71 | IMPDH2 (0.37) | IMPDH2IMPDH1HPGDSTING1PDE3B | |
| SCHEMBL10072473 | 0.70 | STING1 (0.32) | TAAR1STING1 | |
| SCHEMBL16473371 | 0.70 | HPGD (0.44) | IMPDH2IMPDH1HPGDTAAR1STING1 | |
| SCHEMBL16473385 | 0.70 | HPGD (0.44) | IMPDH2IMPDH1HPGDTAAR1STING1 | |
| SCHEMBL16473387 | 0.70 | HINT1 (0.36) | IMPDH2IMPDH1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268980-B2 | 5′-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120010393-A1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010393-A1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NT5C3B, NSUN2, ADAR | IMPDH2 302/4885IMPDH1 231/4885HPGD 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.